Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04764344 · ClinicalTrials.gov registry record · Phase 4
Haloperidol for the Treatment of Nausea and Vomiting in the ED
A Phase 4 study, sponsored by Western Michigan University School of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT04764344: Completed Phase 4 study, sponsored by Western Michigan University School of Medicine.
NCT04764344 is a Phase 4 study that has completed, run by Western Michigan University School of Medicine. The registered enrollment target is 60 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04764344, a Phase 4 study, has completed, sponsored by Western Michigan University School of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
Single center, double-blind, randomized, controlled trial in patients who present to the emergency department (ED) with a chief complaint of nausea or vomiting. A total of 300 patients age 18-55 presenting to the emergency department with chief complaint of nausea or vomiting will be enrolled from February 2021 - February 2022. Patients will be randomized and symptom levels will be recorded at 30, 60, 90, minutes. Follow-up will be performed by telephone at 24 hours.
Primary Outcome
Mean change in visual analog scale (VAS) of self-rated nausea severity
Interventions
- DRUG Haloperidol
- DRUG Ondansetron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2023-05-22 |
| Phase | Phase 4 |
What the finished NCT04764344 record still lists
NCT04764344 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Haloperidol is the first listed.
NCT04764344 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04764344 about?
NCT04764344 is a clinical study titled "Haloperidol for the Treatment of Nausea and Vomiting in the ED". Single center, double-blind, randomized, controlled trial in patients who present to the emergency department (ED) with a chief complaint of nausea or vomiting. A total of 300 patients age 18-55 presenting to the emergency department with chief complaint of nausea or vomiting will be enrolled from F...
What is the current status of trial NCT04764344?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2021-04-01. Estimated completion is 2023-05-22.
What interventions are being tested in trial NCT04764344?
The interventions under investigation include: Haloperidol (DRUG), Ondansetron (DRUG).
Who is sponsoring clinical trial NCT04764344?
This trial is sponsored by Western Michigan University School of Medicine, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04764344's enrollment target sits among peer trials
60 1125th of 2000 higher than 799 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI